RxDoctor Payments Data

Hareem Arif

Psychiatry · Bowling Green, KYNPI 1134757974

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 192 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,538, 7.4 times the $342 reported in 2022.

$3,912in general payments, 2019–2025

Across 192 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$644
  • AbbVie$595
  • Axsome Therapeutics, Inc.$453
  • Johnson & Johnson$443
  • Otsuka America Pharmaceutical, Inc.$401
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$376
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,912100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,912 in reported general payments places this provider in the 80th percentile of 348 psychiatry providers in Kentucky.

See all psychiatry providers in Kentucky

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate16$27,469
VraylarCariprazine Hcl13$19,595
SpravatoEsketamine Hcl14$15,785
AuvelityDextromethorphan Hbr/Bupropion11$12,569
Lurasidone Hcl18$4,474
Aripiprazole50$3,959
Divalproex Sodium ErDivalproex Sodium20$2,638
Quetiapine Fumarate120$2,484
Duloxetine Hcl122$2,363
Quetiapine Fumarate ErQuetiapine Fumarate20$1,733
Ziprasidone Hcl17$1,578
Doxepin Hcl33$1,411
Trazodone Hcl114$1,377
Buspirone Hcl102$1,325
Clozapine20$1,295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$376$27,46916 claims
AbbVieVraylar$595$19,59513 claims
Johnson & JohnsonSpravato$443$15,78514 claims
Axsome Therapeutics, Inc.Auvelity$453$12,56911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 348 psychiatry providers in Kentucky.

Other psychiatry in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →